132622-69-6Relevant articles and documents
Structure - Activity relationship studies of targeting ligands against breast cancer cells
Yao, Nianhuan,Xiao, Wenwu,Meza, Leah,Tseng, Harry,Chuck, Mathida,Lam, Kit S.
supporting information; experimental part, p. 6744 - 6751 (2010/04/04)
A series of LXY3 (1) analogues were designed and synthesized. Their binding affinity was demonstrated using MDA-MB-231 breast cancer cells adherence inhibition assay. Further structure-activity relationship was obtained. Analogue 29 was discovered to have 3.5-fold increase of the binding affinity. Fluorescent microscopy and in vivo and ex vivo imaging studies demonstrated that 29 is an efficient in vivo targeting agent against α3 integrin of MDA-MB-231 breast tumor xenograft implant. 2009 American Chemical Society.
Inhibitors of Hepatitis C Virus
-
Page/Page column 78-79, (2008/12/04)
Macrocyclic peptides are disclosed having the general formula: wherein R3, R′3, R4, R6, R′, X, Q and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.
Hepatitis C virus inhibitors
-
Page/Page column 81, (2010/11/26)
Macrocyclic peptides are disclosed having the general formula: wherein R′, R3, R3′, R4, R6, X, Q, and W are described. Compositions comprising the compounds and methods for using the compounds to inhibit HCV are also disclosed.